POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

U.S. FDA seeks new warnings on drugs from Pfizer, Lilly and AbbVie

Christian Fernsby |
The U.S. drugs regulator on Wednesday asked Pfizer Inc, Eli Lilly and AbbVie Inc to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors.

Article continues below




JAK inhibitors block inflammation-causing enzymes, known as Janus kinases, and target autoimmune diseases such as rheumatoid arthritis and ulcerative colitis.

The FDA said the Lilly drug Olumiant and AbbVie’s Rinvoq have similar operating mechanisms, leading to the possibility of risks seen in the Xeljanz safety trial.

Incyte Corp’s Jakafi and Bristol Myers Squibb’s JAK inhibitor Inrebic will not need warnings as they are not approved to treat inflammatory conditions, the agency said.


What to read next

Eli Lilly is seeking an EUA for bamlanivimab and etesevimab together from FDA as COVID treatment
U.S. cigarette packages to carry new health warnings
Dramatic increase in e-cigarette use among youth in U.S.